Phenytoin Sodium Cap



Indications and Reactions:

Role Indications Reactions
Primary
Convulsion 41.5%
Epilepsy 25.6%
Hypertension 4.0%
Convulsion Prophylaxis 3.4%
Grand Mal Convulsion 3.4%
Partial Seizures 2.8%
Brain Injury 2.3%
Prophylaxis 2.3%
Depression 1.7%
Maintenance Of Anaesthesia 1.7%
Arthralgia 1.1%
Atrial Fibrillation 1.1%
Constipation 1.1%
Dizziness 1.1%
Drug Use For Unknown Indication 1.1%
Glioma 1.1%
Hypercholesterolaemia 1.1%
Hyperuricaemia 1.1%
Lennox-gastaut Syndrome 1.1%
Myocardial Ischaemia 1.1%
Stevens-johnson Syndrome 36.2%
Convulsion 14.6%
Drug Ineffective 4.6%
Anticonvulsant Drug Level Below Therapeutic 3.8%
Gastrostomy Tube Insertion 3.8%
Grand Mal Convulsion 3.8%
Rash 3.8%
Death 3.1%
Drug Level Below Therapeutic 3.1%
Epilepsy 3.1%
Therapeutic Agent Toxicity 3.1%
Dysphagia 2.3%
Loss Of Consciousness 2.3%
Nausea 2.3%
Therapeutic Response Unexpected With Drug Substitution 2.3%
Anticonvulsant Drug Level Above Therapeutic 1.5%
Blood Pressure Increased 1.5%
Drug Effect Decreased 1.5%
Hair Texture Abnormal 1.5%
Hallucination 1.5%
Secondary
Epilepsy 33.9%
Convulsion 17.6%
Product Used For Unknown Indication 12.2%
Drug Use For Unknown Indication 4.5%
Status Epilepticus 3.6%
Partial Seizures With Secondary Generalisation 2.9%
Depression 2.7%
Grand Mal Convulsion 2.7%
Hypertension 2.4%
Encephalitis 2.2%
Complex Partial Seizures 2.0%
Gastritis Prophylaxis 2.0%
Tuberous Sclerosis 2.0%
Convulsion Prophylaxis 1.6%
Altered State Of Consciousness 1.3%
Constipation 1.3%
Headache 1.3%
Infection 1.3%
Partial Seizures 1.3%
Back Pain 1.1%
Epilepsy 10.3%
Cyanosis 7.7%
Drug Ineffective 6.4%
Headache 6.4%
Liver Disorder 6.4%
Stevens-johnson Syndrome 6.4%
Convulsion 5.1%
Drug Level Below Therapeutic 5.1%
Drug Rash With Eosinophilia And Systemic Symptoms 5.1%
Loss Of Consciousness 5.1%
Altered State Of Consciousness 3.8%
C-reactive Protein Increased 3.8%
Drug Eruption 3.8%
Gingival Hyperplasia 3.8%
Incontinence 3.8%
Lymphadenopathy 3.8%
Nikolsky's Sign 3.8%
Poor Venous Access 3.8%
Agranulocytosis 2.6%
Blood Pressure Increased 2.6%
Concomitant
Epilepsy 28.3%
Prophylaxis 15.8%
Drug Use For Unknown Indication 8.4%
Convulsion 6.4%
Pneumonia 4.9%
Hypertension 3.9%
Complex Partial Seizures 3.4%
Product Used For Unknown Indication 3.1%
Cerebrovascular Accident Prophylaxis 2.9%
Insomnia 2.6%
Breast Cancer Recurrent 2.4%
Metastases To Bone 2.4%
Simple Partial Seizures 2.4%
Bipolar I Disorder 2.3%
Anticoagulant Therapy 1.9%
Convulsion Prophylaxis 1.9%
Infection 1.9%
Anaemia 1.8%
Nuclear Magnetic Resonance Imaging 1.6%
Cerebral Infarction 1.5%
Epilepsy 12.7%
Urine Abnormality 7.6%
Pyrexia 6.8%
Pancytopenia 5.9%
Potentiating Drug Interaction 5.9%
Abnormal Behaviour 5.1%
Agranulocytosis 5.1%
White Blood Cell Count Increased 5.1%
Caesarean Section 4.2%
Death 4.2%
Hepatic Function Abnormal 4.2%
Respiratory Arrest 4.2%
Weight Decreased 4.2%
White Blood Cell Count Decreased 4.2%
Cerebral Infarction 3.4%
Convulsion 3.4%
Delirium 3.4%
Dysphagia 3.4%
Loss Of Consciousness 3.4%
Platelet Count Decreased 3.4%
Interacting
Immunosuppression 28.3%
Drug Use For Unknown Indication 17.0%
Epilepsy 13.2%
Pneumonia 11.3%
Pain 7.5%
Fungaemia 5.7%
Grand Mal Convulsion 5.7%
Migraine 3.8%
Status Epilepticus 3.8%
Suicide Attempt 3.8%
Overdose 43.8%
Kidney Transplant Rejection 18.8%
Epilepsy 12.5%
Weight Decreased 12.5%
Haemodynamic Instability 6.3%
Renal Failure 6.3%